Preinterventional Clopidogrel Response Variability for Coil Embolization of Intracranial Aneurysms: Clinical Implications

References

1. 1.↵
   1. Pelz DM,
   2. Lownie SP,
   3. Fox AJ

   . Thromboembolic events associated with the treatment of cerebral aneurysms with Guglielmi detachable coils. AJNR Am J Neuroradiol 1998;19:1541–47

   Abstract
2. 2.↵
   1. Derdeyn CP,
   2. Cross DT 3rd.,
   3. Moran CJ,
   4. et al

   . Postprocedure ischemic events after treatment of intracranial aneurysms with Guglielmi detachable coils. J Neurosurg 2002;96:837–43

   PubMedWeb of Science
3. 3.↵
   1. Park HK,
   2. Horowitz M,
   3. Jungreis C,
   4. et al

   . Periprocedural morbidity and mortality associated with endovascular treatment of intracranial aneurysms. AJNR Am J Neuroradiol 2005;26:506–14

   Abstract/FREE Full Text
4. 4.↵
   1. Ross IB,
   2. Dhillon GS

   . Complications of endovascular treatment of cerebral aneurysms. Surg Neurol 2005;64:12–19

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Brooks NP,
   2. Turk AS,
   3. Niemann DB,
   4. et al

   . Frequency of thromboembolic events associated with endovascular aneurysm treatment: retrospective case series. J Neurosurg 2008;108:1095–100

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Ries T,
   2. Buhk JH,
   3. Kucinski T,
   4. et al

   . Intravenous administration of acetylsalicylic acid during endovascular treatment of cerebral aneurysms reduces the rate of thromboembolic events. Stroke 2006;37:1816–21

   Abstract/FREE Full Text
7. 7.↵
   1. Yamada NK,
   2. Cross DT 3rd.,
   3. Pilgram TK,
   4. et al

   . Effect of antiplatelet therapy on thromboembolic complications of elective coil embolization of cerebral aneurysms. AJNR Am J Neuroradiol 2007;28:1778–82

   Abstract/FREE Full Text
8. 8.↵
   1. Dorsam RT,
   2. Kunapuli SP

   . Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004;113:340–45

   CrossRefPubMedWeb of Science
9. 9.↵
   A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee. Lancet 1996;348:1329–39

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Yusuf S,
    2. Zhao F,
    3. Mehta SR,
    4. et al

    . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Steinhubl SR,
    2. Berger PB,
    3. Mann JT 3rd.,
    4. et al

    . Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411–20

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Diener HC,
    2. Bogousslavsky J,
    3. Brass LM,
    4. et al

    . Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–37

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Bhatt DL,
    2. Fox KA,
    3. Hacke W,
    4. et al

    . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–17

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Gurbel PA,
    2. Bliden KP,
    3. Hiatt BL,
    4. et al

    . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–13

    Abstract/FREE Full Text
15. 15.↵
    1. Serebruany VL,
    2. Steinhubl SR,
    3. Berger PB,
    4. et al

    . Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246–51

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Kwon BJ,
    2. Han MH,
    3. Oh CW,
    4. et al

    . Anatomical and clinical outcomes after endovascular treatment for unruptured cerebral aneurysms: a single center experience. Interventional Neuroradiology 2002;8:367–76

    PubMed
17. 17.↵
    1. Kwon BJ,
    2. Han MH,
    3. Oh CW,
    4. et al

    . Procedure-related haemorrhage in embolisation of intracranial aneurysms with Guglielmi detachable coils. Neuroradiology 2003;45:562–69. Epub 2003 Jul 8

    CrossRefPubMed
18. 18.↵
    1. Kwon OK,
    2. Kim SH,
    3. Kwon BJ,
    4. et al

    . Endovascular treatment of wide-necked aneurysms by using two microcatheters: techniques and outcomes in 25 patients. AJNR Am J Neuroradiol 2005;26:894–900

    Abstract/FREE Full Text
19. 19.↵
    1. Kwon OK,
    2. Kim SH,
    3. Oh CW,
    4. et al

    . Embolization of wide-necked aneurysms with using three or more microcatheters. Acta Neurochir (Wien) 2006;148:1139–45, discussion 1145. Epub 2006 Sep 29

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Moret J,
    2. Cognard C,
    3. Weill A,
    4. et al

    . Reconstruction technic in the treatment of wide-neck intracranial aneurysms: long-term angiographic and clinical results—apropos of 56 cases [in French];. J Neuroradiol 1997;24:30–44

    PubMedWeb of Science
21. 21.↵
    1. Higashida RT,
    2. Smith W,
    3. Gress D,
    4. et al

    . Intravascular stent and endovascular coil placement for a ruptured fusiform aneurysm of the basilar artery: case report and review of the literature. J Neurosurg 1997;87:944–9

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Kwon BJ,
    2. Chang HW,
    3. Youn SW,
    4. et al

    . Intracranial aneurysm perforation during endosaccular coiling: impact on clinical outcome, initial occlusion, and recanalization rates. Neurosurgery 2008;63:676–83

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Lee DH,
    2. Arat A,
    3. Morsi H,
    4. et al

    . Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 2008;29:1389–94

    Abstract/FREE Full Text
24. 24.↵
    1. Price MJ,
    2. Nayak KR,
    3. Barker CM,
    4. et al

    . Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;103:1339–43

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Malinin A,
    2. Pokov A,
    3. Swaim L,
    4. et al

    . Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006;28:315–22

    CrossRefPubMedWeb of Science
26. 26.↵
    1. von Beckerath N,
    2. Pogatsa-Murray G,
    3. Wieczorek A,
    4. et al

    . Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006;95:910–11

    PubMedWeb of Science
27. 27.↵
    1. Paniccia R,
    2. Antonucci E,
    3. Gori AM,
    4. et al

    . Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007;5:1839–47

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Jakubowski JA,
    2. Payne CD,
    3. Li YG,
    4. et al

    . The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008;99:409–15

    PubMedWeb of Science
29. 29.↵
    1. Barsky AA,
    2. Arora RR

    . Clopidogrel resistance: myth or reality? J Cardiovasc Pharmacol Ther 2006;11:47–53

    Abstract/FREE Full Text
30. 30.↵
    1. Prabhakaran S,
    2. Wells KR,
    3. Lee VH,
    4. et al

    . Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281–85

    Abstract/FREE Full Text
31. 31.↵
    1. Patti G,
    2. Nusca A,
    3. Mangiacapra F,
    4. et al

    . Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128–33

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Scandlyn MJ,
    2. Stuart EC,
    3. Rosenglen RJ

    . Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 2008;4:413–24

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Jeong YH,
    2. Lee SW,
    3. Choi BR,
    4. et al

    . Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009;53:1101–09

    CrossRefPubMed
34. 34.↵
    1. Wiviott SD,
    2. Braunwald E,
    3. McCabe CH,
    4. et al

    . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Mega JL,
    2. Close SL,
    3. Wiviott SD,
    4. et al

    . Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354–62

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Simon T,
    2. Verstuyft C,
    3. Mary-Krause M,
    4. et al

    . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363–75

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Collet JP,
    2. Hulot JS,
    3. Pena A,
    4. et al

    . Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309–17

    CrossRefPubMedWeb of Science